

# Journal Club Spotlights: Current Advancements in Non-Small Cell Lung Cancer



## Key Concepts

### Setidegrasib

- Setidegrasib is a novel, first-in-class intravenous KRASG12D targeting protein degrader with beneficial antitumor activity profile and manageable safety profile in patients with previously treated advanced or metastatic non-small cell lung cancer harboring a KRASG12D mutation
- With promising clinical and tolerability data, infusion reactions with cycle 1 and nausea were the most common adverse events, setidegrasib appears to be a promising novel therapeutic option to be considered for possible combination strategies with standard of care therapies, including immunotherapy for patients with non-small cell lung cancer and a KRASG12D mutation